Skip to content

Adarx Pharmaceuticals

US · ADRX #2823 by market cap Listed 2026
12.79 -1.37 -9.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 26 in the most recent period (2026/Q3).
  • Total institutional ownership rose 62.3 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
62.31% +62.31pp
Institutions
26 +26
As of
2026/Q3 vs. prior period

Holder types

VC/PE Fund46.50%
Mutual Fund11.12%
Individual/Insider7.47%
Private Company4.63%
Other30.22%

Top holders as of 2026-10-02

OrbiMed Advisors LLC 22.13% · 24.79M sh
Eli Lilly Investment Consulting (Shanghai) Co., Ltd. 10.58% · 11.86M sh
SR One Capital Management, LP 8.87% · 9.94M sh
Li Zhen 5.23% · 5.86M sh
Zhen Li 5.23% · 5.86M sh
Bcls Fund III Investments, Lp 4.58% · 5.13M sh
FMR 3.25% · 3.65M sh
TCG Crossover Management, LLC 3.20% · 3.59M sh
Capital Research 2.97% · 3.33M sh
T. Rowe Price Group, Inc. 1.75% · 1.96M sh
Columbia Management Investment Advisers, LLC 0.01% · 8.52K sh
Rui Zhu 2.24% · 2.51M sh
Franklin Resources 0.42% · 466.39K sh
BlackRock 2.08% · 2.34M sh
Vanguard Capital Management, LLC 0.04% · 50.09K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

19 filings tracked · 10 buys · 0 sells

NameRoleStake
OrbiMed Advisors LLC -- 22.13%
Eli Lilly Investment Consulting (Shanghai) Co., Ltd. -- 10.58%
Li Zhen Chief Executive Officer 5.23%
Rui Zhu Chief Technology Officer 2.24%
Mary Tagliaferri Independent Director --
Ying Huang Independent Director --
SR One Capital Management, LP -- --
Robert Ackles Chief Human Resources Officer --
A. MacLeod Chief Scientific Officer --
Ryan Fisk CFO & Chief Business Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-27 OrbiMed Advisors LLC -- Private Acquisition +950,000 $17.00
2026-09-27 OrbiMed Advisors LLC -- Derivative Exercise and Retained +23,255,789 --
2026-09-27 Eli Lilly Investment Consulting (Shanghai) Co., Ltd. -- Derivative Exercise and Retained +11,858,655 --
2026-09-27 SR One Capital Management, LP -- Private Acquisition +1,600,000 $17.00
2026-09-27 SR One Capital Management, LP -- Derivative Exercise and Retained +8,336,661 --
2026-09-23 Mary Tagliaferri Independent Director Initial Statement of Beneficial 0 --
2026-09-23 Ying Huang Independent Director Initial Statement of Beneficial 0 --
2026-09-23 Li Zhen Chief Executive Officer Other Derivative Acquisition +1,024,152 $17.00
2026-09-23 Li Zhen Chief Executive Officer Initial Statement of Beneficial 0 --
2026-09-23 Robert Ackles Chief Human Resources Officer Other Derivative Acquisition +85,346 $17.00
2026-09-23 Robert Ackles Chief Human Resources Officer Initial Statement of Beneficial 0 --
2026-09-23 A. MacLeod Chief Scientific Officer Other Derivative Acquisition +170,692 $17.00
2026-09-23 A. MacLeod Chief Scientific Officer Initial Statement of Beneficial 0 --
2026-09-23 Ryan Fisk CFO & Chief Business Officer Other Derivative Acquisition +170,692 $17.00
2026-09-23 Ryan Fisk CFO & Chief Business Officer Initial Statement of Beneficial 0 --
2026-09-23 Rui Zhu Chief Technology Officer Other Derivative Acquisition +512,076 $17.00
2026-09-23 Rui Zhu Chief Technology Officer Initial Statement of Beneficial 0 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Adarx Pharmaceuticals discussion 0 comments

Add a comment